Trial Profile
Single ascending dose study of the safety, tolerability, and pharmacokinetics of LXR-623 administered orally to healthy Japanese male subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2007
Price :
$35
*
At a glance
- Drugs LXR 623 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Wyeth
- 20 Sep 2007 In September 2007, Wyeth discontinued development of LXR 623, as it had an unfavourable proflie for further development.
- 20 Sep 2007 Status change from recruiting to discontinued
- 22 Mar 2007 New trial record.